ClinicalTrials.gg

Program

BRD4 Degrader MT-4561

Its studies are mostly in Squamous Cell Carcinoma of Head and Neck, led by Tanabe Pharma.

Furthest: phase 2, since Mar 28, 20251 company-led study, 1 open or runningNext primary completion: Aug 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tanabe Pharma11 open or runningphase 2since Mar 28, 2025Mar 28, 2025Aug 2028phase 2 · NCT06943521

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 28, 2025First study: phase 2 study in Squamous Cell Carcinoma of Head and NeckFirst studyNCT06943521 · 27 planned · United States, Japan

Ahead

  1. Aug 2028Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT06943521

TargetBeta

BRD4 →read by rule
“A degrader of bromodomain-containing protein 4 (BRD4), ”NCIt, by rule

Other programs on BRD4

ProgramCompanyFurthest phaseStudies
pelabresibruleNovartisphase 311
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915Johnson & Johnsonphase 33

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06943521Squamous Cell Carcinoma of Head and Neck · United States, Japan2RecruitingAug 202827

How it is read

Names in the registry

  • “MT-4561”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.